Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Viatris (VTRS) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This generic drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 6.38%.For the last reported quarter, Viatris came out with earn ...

​Viatris Inc. (NASDAQ:VTRS) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 15, Viatris Inc. (NASDAQ:VTRS) announced completing the acquisition of Aculys Pharma, Inc., which is a clinical-stage biopharmaceutical company. ​Aculys Pharma, Inc. is commercializing innovative treatments for neurological conditions. Management noted that, as a result of this acquisition, Viatris Inc. (NASDAQ:VTRS) has received rights to develop and commercialize Pitolisant and Spydia, which are two impor ...

Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] Company Mission - The mission of Allka Research is to empower individuals financially by sharing knowledge and insights through platforms like Seeking Alpha [1] - The company aims to provide thought-provoking analyses and informed perspectives to foster a community of informed investors [1] - Allka Research seeks to demystify investing, inspiring confidence in readers to navigate the financial markets intelligently [1]

Core Insights - Viatris (VTRS) has acquired Tokyo-based Aculys Pharma, focusing on enhancing its Central Nervous System (CNS) portfolio and expanding its presence in Japan and the Asia-Pacific region [1][3][6] Acquisition Details - The acquisition involves an undisclosed upfront payment to Aculys Pharma's shareholders, with additional payments linked to regulatory and commercial milestones, as well as royalties based on net sales [2] - Viatris has secured exclusive rights to develop and commercialize pitolisant and Spydia (diazepam nasal spray) in Japan and select Asia-Pacific markets [1][6][7] Product Information - Pitolisant is a selective/inverse agonist of the histamine H3 receptor, with plans for marketing approval in Japan by the end of 2025 for treating excessive daytime sleepiness (EDS) and cataplexy in narcolepsy patients [4][9] - Spydia, approved in June 2025 in Japan, is the first intranasal anti-seizure medication for status epilepticus, addressing unmet needs in neurological emergencies [7][8] Strategic Rationale - The acquisition aims to leverage Viatris' commercial infrastructure and CNS expertise, aligning with its strategy to grow in high-impact therapeutic areas [9][10] - This move complements Viatris' existing innovative portfolio in Japan, which includes products for various conditions, thereby positioning the company for near- and mid-term growth [10]

Accessibility StatementSkip Navigation PITTSBURGH, Oct. 15, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has acquired Aculys Pharma, Inc., a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions. Viatris received rights to develop and commercialize pitolisant and Spydia, two assets in the Central Nervous System (CNS) therapy area, further expanding Viatris' portfolio of innovative products in ...

, /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2025. This is the fifth year in a row that Viatris has received this recognition, which is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider. "Being included once again on the Forbes' World's Best Employers 2025 list is a great way to mark our company's upcoming fifth anniversary and a testament to our ...

Viatris (NASDAQ:VTRS) shares snapped six straight sessions of gains on Monday, as the stock closed 0.6% lower at $10.13. The healthcare gained 7% in the preceding six sessions. Overall, the stock has lost over 13% so far this year, compared to the 14% rise in the broader ...

Group 1 - The Conservative Income Portfolio focuses on value stocks with high margins of safety and aims to reduce volatility through well-priced options [1][2] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - The Covered Calls Portfolio aims for lower volatility income investing with an emphasis on capital preservation [1][2] Group 2 - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income and capital preservation [2] - The investing group operates the Conservative Income Portfolio in partnership with Preferred Stock Trader, featuring two income-generating portfolios and a bond ladder [2]

Group 1 - The Conservative Income Portfolio aims to target the best value stocks with high margins of safety while reducing volatility through well-priced options [1] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - The Covered Calls Portfolio focuses on lower volatility income investing with an emphasis on capital preservation [1] Group 2 - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income and capital preservation [2] - The investing group operates the Conservative Income Portfolio in partnership with Preferred Stock Trader, featuring two income-generating portfolios and a bond ladder [2]

Company Overview - Viatris Inc. (NASDAQ:VTRS) was formed from the 2020 merger of Mylan and Pfizer's Upjohn division, delivering essential generic and specialty medicines to patients in over 165 countries [1] - The company maintains a broad portfolio across multiple therapeutic areas, focusing on sustainable growth, operational discipline, and shareholder returns [1] Recent Developments - In September 2025, Viatris achieved FDA approval for its first generic Iron Sucrose Injection, a complex generic version of Venofer, which is intended for iron deficiency anemia in chronic kidney disease patients [2] - The injection is available in three strengths, with two awarded Competitive Generic Therapy designation, granting 180 days of market exclusivity [2] - Venofer generates $515 million in annual U.S. sales, and this approval significantly strengthens Viatris' injectable portfolio [2] Financial Performance - Viatris reported strong Q2 2025 results, with revenues of $3.58 billion and adjusted EPS of $0.62, exceeding expectations while maintaining top-half guidance for the year [3] - The firm returned over $630 million to shareholders year-to-date, including $350 million in share buybacks [3] Research and Development - Pipeline progress includes positive outcomes from five Phase 3 studies, notably in ophthalmic solutions for night vision impairment and presbyopia, supporting upcoming FDA submissions [3] - Presentations at PAINWeek 2025 highlighted Viatris' R&D capabilities and commitment to clinical innovation in pain management [4] Leadership Changes - Andrew Enrietti was appointed Chief Administrative and Transformation Officer, and David Simmons joined the board to strengthen strategic oversight [4]